Last reviewed · How we verify
Ivermectin (reference)
Ivermectin binds to glutamate-gated chloride channels in parasitic organisms, causing paralysis and death of the parasite.
Ivermectin binds to glutamate-gated chloride channels in parasitic organisms, causing paralysis and death of the parasite. Used for Onchocerciasis (river blindness), Lymphatic filariasis, Strongyloidiasis.
At a glance
| Generic name | Ivermectin (reference) |
|---|---|
| Sponsor | Padagis LLC |
| Drug class | Antiparasitic agent |
| Target | Glutamate-gated chloride channels (GluCl) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Ivermectin is a macrocyclic lactone that selectively binds to invertebrate-specific glutamate-gated chloride ion channels, increasing chloride conductance and hyperpolarizing the cell membrane. This leads to paralysis and death of susceptible parasites. The drug has high selectivity for parasitic channels over mammalian GABA receptors, making it relatively safe for human use.
Approved indications
- Onchocerciasis (river blindness)
- Lymphatic filariasis
- Strongyloidiasis
- Scabies
- Lice infestations
Common side effects
- Pruritus
- Headache
- Dizziness
- Arthralgia
- Mazzotti reaction (fever, lymphadenitis)
Key clinical trials
- Ivermectin to Prevent SARS-CoV-2 (COVID-19) Hospitalisation in Subjects Over 50 (PHASE3)
- Bioequivalence of a Single-dose of 12 mg IVERMECTIN as Orally Disintegrating Mini Tablets Versus a Single-dose of 12 mg Regular IVERMECTIN Tablets in Healthy Adults Under Fasting Conditions (EARLY_PHASE1)
- Comparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea (PHASE3)
- Bioequivalence Study of Ivermectin From Revemact 6 mg Tablets (Man. by EVA Pharma for Horus for Pharmaceutical Industries, Egypt) and Stromectol 2*3 mg Tablets (Merck Sharp & Dohme B.V., Haarlem, The Netherlands) (PHASE1)
- Bioequivalence Study of Ivermectin Cream 1% in Treatment of Moderate to Severe Facial Rosacea (PHASE3)
- A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice (PHASE3)
- Clinical Endpoint Study of Ivermectin 1% Cream (PHASE3)
- Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA®, Abbott Laboratórios do Brasil Ltda, Brazil) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ivermectin (reference) CI brief — competitive landscape report
- Ivermectin (reference) updates RSS · CI watch RSS
- Padagis LLC portfolio CI